Spots Global Cancer Trial Database for phase 1
Every month we try and update this database with for phase 1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | NCT01930006 | Advanced Malign... | MGCD265 | 18 Years - 55 Years | Mirati Therapeutics Inc. | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients | NCT00692159 | Neoplasm | TRC102 + pemetr... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| FHD-286 in Subjects With Metastatic Uveal Melanoma | NCT04879017 | Metastatic Uvea... | FHD-286 | 18 Years - | Foghorn Therapeutics Inc. | |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | NCT02157636 | Multiple Myelom... | CPI-0610 | 18 Years - | Constellation Pharmaceuticals | |
| Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors | NCT01415297 | Solid Tumors | NKP-1339 | 18 Years - | Intezyne Technologies, Inc. | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Erlotinib and Sunitinib in NSCLC | NCT00581789 | Non Small Cell ... | erlotinib, suni... | 18 Years - | University of Wisconsin, Madison | |
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | NCT03027128 | Solid Tumor | haNK™ for Infus... | 18 Years - | ImmunityBio, Inc. | |
| A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | NCT01957007 | Solid Tumors | Docetaxel vantictumab | 18 Years - 90 Years | Mereo BioPharma | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors | NCT00977210 | Solid Tumors | OXi4503 | 18 Years - | Mateon Therapeutics | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | NCT01014936 | Patients With S... | MSC2156119J | 18 Years - | EMD Serono | |
| Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | NCT01705002 | Cancer Solid Tumor Metastatic Colo... | Promitil Capecitabine Bevacizumab | 18 Years - 80 Years | Lipomedix Pharmaceuticals Inc. | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | NCT02003092 | Solid Tumor Triple Negative... | RX-5902 | 18 Years - | Rexahn Pharmaceuticals, Inc. | |
| Study of LP-184 in Patients With Advanced Solid Tumors | NCT05933265 | Advanced Solid ... | LP-184 | 18 Years - | Lantern Pharma Inc. | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | NCT00159484 | Colon Cancer Colorectal Canc... | EPO906, celecox... | 18 Years - | University of Southern California | |
| Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02278315 | Multiple Myelom... | I-131-CLR1404 dexamethasone I-131-CLR1404 | 18 Years - | Cellectar Biosciences, Inc. | |
| Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | NCT03916510 | Locally Advance... | Enadenotucirev Capecitabine Radiotherapy | 18 Years - | University of Oxford | |
| Phase 1 Study of Oral TP-1454 | NCT04328740 | Advanced Solid ... Anal Cancer | TP-1454 monothe... | 18 Years - | Sumitomo Pharma America, Inc. | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors | NCT01386866 | Advanced Solid ... | AMG 706 | 18 Years - | Amgen | |
| Study of AMV564 in Patients With AML | NCT03144245 | Acute Myeloid L... | AMV564 AMV564 in combi... | 18 Years - | Amphivena Therapeutics, Inc. | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | NCT01380756 | Cancer Hematologic Mal... Leukemia Myeloid Leukemi... | Arm 1- Dose Esc... Arm 2- Dose Exp... | 18 Years - | Amgen | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors | NCT01673438 | Advanced Solid ... | aldoxorubicin | 18 Years - | ImmunityBio, Inc. | |
| Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | NCT00183742 | Cancer Carcinoma | liposomal doxor... | 18 Years - | University of Southern California | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
| RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX | NCT01049620 | Advanced Gastri... | RAD001, Capecit... | 18 Years - 70 Years | Asan Medical Center | |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors | NCT04009460 | Solid Tumors Neoplasms Malignant Tumor | ES101 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | NCT00528619 | Neoplasms | Sunitinib, Peme... | 18 Years - | Pfizer | |
| A Study of Radiation With Sorafenib in Advanced Cancer | NCT00610246 | Cancer | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | NCT05469919 | Advanced Solid ... | Ceralasertib | 18 Years - | AstraZeneca | |
| A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT02705469 | Metastatic Cast... | ZEN003694 | 18 Years - | Zenith Epigenetics | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Study Of PF-06664178 In Patients With Advanced Solid Tumors | NCT02122146 | Neoplasms | PF-06664178 PF-06664178 | 18 Years - | Pfizer | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | NCT01302405 | Advanced Solid ... | PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | NCT01302405 | Advanced Solid ... | PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies | NCT01924689 | Solid Tumor Mal... | Clostridium nov... | 18 Years - | BioMed Valley Discoveries, Inc | |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | NCT04053673 | Solid Tumor, Ad... | RBN-2397 | 18 Years - | Ribon Therapeutics, Inc. | |
| A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | NCT01832506 | Solid Tumors | MSC2156119J | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors | NCT04730843 | Solid Tumors Neoplasms Malignant Tumor | ES102 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | NCT02824042 | Medical Oncolog... | Anetumab ravtan... Itraconazole | 18 Years - | Bayer | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | NCT00390156 | Unspecified Adu... | bevacizumab cyclophosphamid... imatinib | 18 Years - | University of California, San Francisco | |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | NCT00858377 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | Arm 1- Dose Esc... Arm 1- Dose Exp... | 18 Years - | Amgen | |
| 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | NCT04689347 | Metastatic Colo... | Bevacizumab Irinotecan Leucovorin 5Fluorouracil Temozolomide | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03248843 | Advanced or Met... | KN035 | 20 Years - | 3D Medicines | |
| A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | NCT00728468 | Advanced Malign... | PF-00299804 | 18 Years - | Pfizer | |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | NCT01684150 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... | EPZ-5676 | 18 Years - 90 Years | Ipsen | |
| A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | NCT04014257 | Phase 1 Solid Tumor, Ad... | NOV1601(CHC2014... | 19 Years - | Handok Inc. | |
| Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 | NCT01634503 | Cervical Intrae... | GX-188E adminis... | 20 Years - 50 Years | Genexine, Inc. | |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | NCT04834778 | Renal Cell Carc... Gastric Cancer Metastatic Brea... Small-cell Lung... Other Solid Tum... | HC-5404-FU | 18 Years - | HiberCell, Inc. | |
| Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors | NCT00183833 | Colon Cancer Colorectal Canc... | capecitabine, i... | 18 Years - | University of Southern California | |
| Phase 1 Study of Oral TP-1454 | NCT04328740 | Advanced Solid ... Anal Cancer | TP-1454 monothe... | 18 Years - | Sumitomo Pharma America, Inc. | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Phase 1 Study of ONT-10 in Patients With Solid Tumors | NCT01556789 | Solid Tumors | ONT-10 | 18 Years - 70 Years | Seagen Inc. | |
| A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | NCT01277146 | Solid Tumors | OMP-59R5 | 18 Years - 90 Years | Mereo BioPharma | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | NCT01778439 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors | NCT02004717 | Solid Tumors | DS-8895a | 20 Years - | Daiichi Sankyo | |
| Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | NCT00944801 | Glioblastoma | Pegylated Lipos... | 18 Years - 70 Years | University of Regensburg | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | NCT01608867 | Solid Tumors | OMP-54F28 | 18 Years - 90 Years | Mereo BioPharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
